Two phase III trials (EFECT and SoFEA) showed an interest in ESR1 mutation detection at baseline, as EXE versus FUL was associated with better progression-free survival (PFS) and OS in ER+ BC patients [32]. The gene discussed is ESR1; the disease is breast cancer.